Literature DB >> 11575041

Recent discoveries in assessment of coronary heart disease: impact of vascular mechanisms on development of atherosclerosis.

R J Chilton1.   

Abstract

Until recently, arterial stenosis and occlusion due to buildup of atherosclerotic plaque were recognized as the primary causes of coronary heart disease (CHD). Currently, CHD is viewed as a lifelong process of endothelial inflammation, thrombosis, and plaque instability and rupture. Lifestyle modification is an important first step in prevention of CHD, but even those patients who are the most committed to following a healthy diet and lifestyle frequently require the addition of drug therapy to further reduce risk. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduce risk by lowering low-density lipoprotein cholesterol levels, as well as by stabilizing plaques, restoring endothelial function, and counteracting oxidative and inflammatory processes. Angiotensin-converting enzyme inhibitors also have antiatherogenic properties. Early, aggressive lipid intervention is the key to primary and secondary prevention of CHD.

Entities:  

Mesh:

Year:  2001        PMID: 11575041

Source DB:  PubMed          Journal:  J Am Osteopath Assoc        ISSN: 0098-6151


  3 in total

1.  Sonographic fatty liver, overweight and ischemic heart disease.

Authors:  Yu-Cheng Lin; Huey-Ming Lo; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

2.  HUVECs from newborns with a strong family history of myocardial infarction overexpress adhesion molecules and react abnormally to stimulating agents.

Authors:  A Paez; A R Méndez-Cruz; E Varela; E Rodriguez; J Guevara; L Flores-Romo; L F Montaño; F A Massó
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

3.  Association between serum adropin level and burden of coronary artery disease in patients with non-ST elevation myocardial infarction.

Authors:  Ahmet Göktuğ Ertem; Sefa Ünal; Tolga Han Efe; Burak Açar; Çağrı Yayla; Mevlüt Serdar Kuyumcu; Özgür Kırbaş; Cemal Köseoğlu; Mehmet Kadri Akboğa; Kadriye Gayretli Yayla; Serkan Gökaslan; Sinan Aydoğdu
Journal:  Anatol J Cardiol       Date:  2016-09-28       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.